No Difference in Survival between Neo-Adjuvant Chemotherapy and Neo-Adjuvant Chemoradiation Therapy in Gastric Cardia Cancer Patients: A Contemporary View from the National Cancer Database.

Tsai, C.; Mueller, A.; Maubach, J.; Warschkow, R.; Nussbaum, D. P.; Schmied, B. M.; Blazer, D.; Gloor, B.; Worni, M. (2020). No Difference in Survival between Neo-Adjuvant Chemotherapy and Neo-Adjuvant Chemoradiation Therapy in Gastric Cardia Cancer Patients: A Contemporary View from the National Cancer Database. Digestive surgery, 37(3), pp. 249-257. Karger 10.1159/000501678

Full text not available from this repository. (Request a copy)

INTRODUCTION

Both neo-adjuvant chemoradiation therapy (NACRT) and neo-adjuvant chemotherapy (NAC), in addition to surgical resection of gastric cardia cancer, improves survival outcomes. We assessed whether NACRT or NAC had superior overall survival (OS) and relative survival (RS) outcomes using the National Cancer Database (NCDB).

METHODS

The NCDB from 2006 to 2014 was reviewed to identify non-metastatic adult gastric cardia cancer patients who underwent surgical resection and received NACRT or NAC. Advanced statistical models were applied to assess survival outcomes.

RESULTS

Of the 5,371 patients included, 4,520 (84.2%) were male, the mean age was 61.2 years (SD 10.0), 4,229 (78.7%) underwent NACRT, and 1,142 (21.3%) underwent NAC. NACRT patients more often had an R0 resection compared to NAC (91.4 vs. 86.6%, p < 0.001, respectively). Univariate 5-year OS rates were 40.0% (95% CI 38.2-41.8) for NACRT and 40.1% (37.0-43.6) for NAC (p = 0.302). No differences in OS for NAC vs. NACRT were found after multivariable analysis (hazard ratio [HR] 0.95, 95% CI 0.86-1.05, p = 0.290). There were no survival differences after stepwise, propensity score, RS analyses, nor after near-far-matching (HR 0.94, 95% CI 0.82-1.07, p = 0.332).

CONCLUSIONS

NAC or NACRT yield the same survival outcome for patients with resectable gastric cardia cancer. These data support the need for randomized controlled trials comparing the 2 regimens head-to-head.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Visceral Surgery and Medicine > Visceral Surgery
04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Visceral Surgery and Medicine

UniBE Contributor:

Müller, Alexandra Charlotte; Maubach, Johannes Andreas; Gloor, Beat and Worni, Mathias

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0253-4886

Publisher:

Karger

Language:

English

Submitter:

Lilian Karin Smith-Wirth

Date Deposited:

07 May 2021 11:36

Last Modified:

07 May 2021 11:36

Publisher DOI:

10.1159/000501678

PubMed ID:

31340206

Additional Information:

C.T. and A.M. contributed equally to this work.

Uncontrolled Keywords:

Esophagogastric junction Gastric cardia cancer Neo-adjuvant chemoradiation therapy Neo-adjuvant chemotherapy Siewert II cancer

URI:

https://boris.unibe.ch/id/eprint/139439

Actions (login required)

Edit item Edit item
Provide Feedback